Compare Amgen, Inc. (AMGN) vs Blackrock Inc (BLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Blackrock Inc — how do they compare? Amgen, Inc. trades at $414.39 (market cap $224.14B), while Blackrock Inc trades at $1,150.09 (market cap $177.92B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | BLK | |
|---|---|---|
Market Cap | $224.14B | $177.92B |
Sector | Health | Financials |
52-Week High | $417.20 | $1.20K |
52-Week Low | $271.18 | $922.90 |
Enterprise Value | $267.45B | $179.02B |
Dividend Yield | 2.43% | 2% |
Volume | — | 641,547 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
BLK trades at $1,131.40, down slightly by 0.44% today, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $24.22 billion for 2025, with net income of $5.55 billion, and has consistently beaten EPS estimates in recent quarters. Recent news highlights BlackRock's involvement in a major AI financing initiative with Nvidia and other firms.
The outlook remains positive given strong earnings performance and a consensus buy rating from analysts, with a price target of $1,350. Key risks include potential legal challenges from investor lawsuits and volatile cash flow trends, but institutional confidence and strategic partnerships provide a solid foundation for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →
